Disclosed is a process for in vitro detection of an infection by a dengue virus in an individual, including the following steps: contacting a blood sample from the individual with a ligand specific to the NS1 protein of said dengue virus, to capture NS1 protein if it is present in the blood sample, said ligand being immobilized on a solid support; detecting the presence of NS1 protein via a mass spectrometry reading; and if NS1 protein is detected, concluding that the individual has been infected by dengue virus.

Provided herein are compositions, methods, and kits for detecting human Pegivirus 2 (HPgV-2). In certain embodiments, provided herein are HPgV-2 specific nucleic acid probes and primers, and methods for detecting HPgV-2 nucleic acid. In other embodiments, provided herein are HPgV-2 immunogenic composition compositions, methods of treating a subject with immunogenic HPgV-2 peptides, and methods of detecting HPgV-2 subject antibodies in a sample.

The invention provides a lateral flow device and methods for the detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a sample of bodily fluid of an animal or human. The test methods include contacting the sample with a conjugate comprising a recombinant SARS-CoV-2 spike protein antigen that has been conjugated to a detection agent, wherein an antigen-antibody complex is formed between the SARS-CoV-2 spike protein antigen conjugate and SARS-CoV-2 antibodies present in the sample; capturing the formed antigen-antibody complex with an Fc-binding molecule; and detecting the captured complex.

The present invention relates to a process for detecting a virus that include the steps of: taking a biosample (e.g. saliva) suspected of containing a virus, mixing it with a solution comprising nanoparticles having easily detectable properties (e.g. a color) and also comprising contrasting microparticles (e.g. clear or white), each having attached chemical compounds (e.g. antibodies) that selectively bind to the virus to be detected (e.g. SARS-CoV-2). When suitably mixed together, virus present in the biosample may bind to the nanoparticles and to the microparticles, connecting the two. When the mixture is then passed through a microfluidic assembly with dimensions that trap the microparticles but pass unbound nanoparticles, the detection of the presence of nanoparticles bound to the microparticles at the microfluidic filter indicates the presence of the virus to be detected. The process may include a concentration step to accelerate binding the virus to the nano- and micro-particles.

The present disclosure relates to methods and compositions, e.g., kits, for assessing or detecting SARS-CoV-2 antigen(s), e.g., SARS-CoV-2 nucleocapsid protein (N-protein), in a sample or a blood sample, e.g., serum, plasma, dried blood spots (DBS) and/or a saliva sample. Certain applications and uses of the present methods and compositions, e.g., kits, are also provided.

A device for retaining a biological sample, for measuring a concentration of a SARS-CoV2 specific antigen, with SARS-CoV2 antigen-specific and electrochemically active immunoreceptor that is conjugated with an electrochemically active substance and optionally including an electrode reactivity enhancement agent and antibody stabilization agent. The immunoreceptor is configured to be in chemical contact with electrodes and a biological sample with SARS-CoV2 specific antigen of the device. The present invention also provides a device holder for holding the device of the present invention and a point-of-care biosensor. A method for measuring a concentration of SARS-CoV2 specific antigen from a reduced volume of biological sample is also provided in the presence of the antigen-specific and electrochemically active immunoreceptor, by measuring a peak value of redox current of the SARS-CoV2 antigen-specific and electrochemically active immunoreceptor and determining a concentration of SARS-CoV2 specific antigen in the biological sample, by linearly matching with a corresponding reference redox current.

The present invention relates to a binding polypeptide specifically binding to the amino acid sequence W-V-N-X.sup.1-F-Y-X.sup.2 (SEQ ID NO: 1), wherein X.sup.1 represents any amino acid, preferably Q or P, and wherein X.sup.2 represents any amino acid, preferably, T or S in a norovirus polypeptide. The present invention further relates to polynucleotide encoding a binding polypeptide of the present invention an to a host cell comprising the same or the polynucleotide of the invention. The present invention further relates to a method of detecting the presence of a norovirus capsid polypeptide in a sample and to kits, devices, and uses making use of the binding peptide of the invention.

Disclosed is a SARS-CoV-2 IgG/IgM detection kit. The kit includes a disposable test cassette and the disposable test cassette includes a base plate, a sample pad, a reaction pad and an absorbent pad. The sample pad, the reaction pad and the absorbent pad are sequentially connected and are provided on the base plate. The sample pad is coated with a colloidal gold-labeled recombinant SARS-CoV-2 S-RBD protein. The reaction pad is provided with a test line and a quality control line. The test line is coated with a mouse anti-human IgG and a mouse anti-human IgM and the quality control line is coated with a goat anti-mouse IgG. The kit provided herein can be used for rapid test of SARS-CoV-2 IgG/IgM, and has high accuracy, good stability and strong anti-interference performance.

The present invention relates to a lateral flow assay device for detection of an analyte in a sample and a method of detection thereof. The present invention provides a quantitative assay for detection of an analyte in a sample. The present invention also provides a conjugate. The present invention provides a method of diagnosing COVID 19 in a patient.

The present disclosure includes a multiplexed peptide assay to generate an epitope-resolved view of antibody reactivity across all human coronaviruses (CoVs). PepSeq accurately classifies SARS-CoV-2 exposure status and reveals epitopes across the Spike and Nucleocapsid proteins. Two of these represent recurrent reactivities to conserved, functionally-important sites in the S2 subunit of Spike, regions that we show are also targeted for the endemic CoVs in pre-pandemic controls. At one of these sites, we demonstrate that the SARS-CoV-2 response strongly and recurrently cross-reacts with the endemic virus hCoV-OC43. The disclosed epitope-resolved analysis reveals new CoV targets for the development of diagnostics, vaccines and therapeutics, including a site that may have broad neutralizing potential.